Elasmogen announces a panel of novel, potent, anti-COVID-19 therapeutic candidates identified through collaboration with U.S. research partners
The Pharma Data
JANUARY 24, 2021
” About Elasmogen: Spun-out from the University of Aberdeen, Scotland in 2016, Elasmogen is developing soloMERs ; fully humanized (or de-immunised) VNAR, as next generation, single chain therapeutics for auto-inflammatory diseases, oncology and intracellular delivery.
Let's personalize your content